Latest Articles
How AI is Helping Researchers Find High-Risk Cancers - TheTyee.ca
How AI is Helping Researchers Find High-Risk Cancers TheTyee.ca
Published: July 17, 2024, 7 a.m.
New study finds popular weight-loss and diabetes medications may be linked to lower risk of some cancers - ABC7 Bay Area
New study finds popular weight-loss and diabetes medications may be linked to lower risk of some cancers ABC7 Bay Area
Published: July 8, 2024, 7 a.m.
AI-based histopathology image analysis reveals a distinct subset of endometrial cancers - Nature.com
AI-based histopathology image analysis reveals a distinct subset of endometrial cancers Nature.com
Published: June 26, 2024, 7 a.m.
Endometriosis increases risks for ovarian, endometrial cancers - Healio
Endometriosis increases risks for ovarian, endometrial cancers Healio
Published: June 7, 2024, 7 a.m.
ASCO Reading Room | Sound Evidence to Treat Smaller, Recurrent Endometrial Cancers With Radiotherapy Alone - Medpage Today
ASCO Reading Room | Sound Evidence to Treat Smaller, Recurrent Endometrial Cancers With Radiotherapy Alone Medpage Today
Published: June 5, 2024, 7 a.m.
For some endometriosis-related ovarian cancers, timing is everything - Medical Xpress
For some endometriosis-related ovarian cancers, timing is everything Medical Xpress
Published: May 28, 2024, 7 a.m.
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses - Nature.com
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses Nature.com
Published: April 23, 2024, 7 a.m.
Genetically identification of endometriosis and cancers risk in women through a two-sample Mendelian randomization study | Scientific Reports - Nature.com
Genetically identification of endometriosis and cancers risk in women through a two-sample Mendelian randomization study | Scientific Reports Nature.com
Published: April 10, 2024, 7 a.m.
The prognostic value of MEK pathway–associated estrogen receptor signaling activity for female cancers - Nature.com
The prognostic value of MEK pathway–associated estrogen receptor signaling activity for female cancers Nature.com
Published: April 6, 2024, 7 a.m.
Trastuzumab Deruxtecan Proves Active in HER2-Expressing Gynecologic Cancers - Cancer Therapy Advisor
Trastuzumab Deruxtecan Proves Active in HER2-Expressing Gynecologic Cancers Cancer Therapy Advisor
Published: March 17, 2024, 7 a.m.
Link copied to clipboard!